Trials / Recruiting
RecruitingNCT06842407
Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Checkmab S.r.l. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.
Conditions
Timeline
- Start date
- 2023-04-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2025-02-24
- Last updated
- 2025-02-24
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06842407. Inclusion in this directory is not an endorsement.